Close Menu

BRAF Biomarkers

News and reporting on BRAF biomarkers.

In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.

The Phase I trial, which will focus on studying BRAF-mutated solid tumors, has enrolled its first patient in Australia and will soon expand to sites in the US.

The study showed that patients with targetable genomic markers, especially HER2 alterations, responded well to chemotherapy-free treatments.

The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.

The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health. 

More individuals treated with BRAF- and MEK-targeted drugs were still alive after four years than would be expected with conventional chemo drugs.

In a study, patients with class 3 BRAF mutations were more likely to respond to an anti-EGFR antibody treatment as a first-or second-line therapy.

An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.

The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.

While the oncology field moves toward NGS panel testing, the drugmaker has launched a program subsidizing single-gene testing for advanced melanoma patients.

Pages